Skip to main content
KRONOX LAB SCIENCES LIMITED logo

KRONOX LAB SCIENCES LIMITED — Investor Relations & Filings

Ticker · KRONOX ISIN · INE0ATZ01017 BSE.NS Manufacturing
Open in API
Filings indexed 96 across all filing types
Latest filing 2026-05-21 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS KRONOX

About KRONOX LAB SCIENCES LIMITED

https://www.kronoxlabsciences.com

Kronox Lab Sciences Limited specializes in the manufacture of High Purity Specialty Fine Chemicals. The company produces a diverse range of products including acetates, carbonates, chlorides, citrates, phosphates, and nitrates, catering to stringent quality standards such as IP, BP, EP, JP, and USP. These chemicals serve as critical inputs for sectors including pharmaceuticals, nutraceuticals, biotechnology, agrochemicals, personal care, and metallurgy. The company emphasizes research and development to provide customized chemical solutions and maintains advanced manufacturing facilities to ensure high-purity outputs. Its product portfolio supports applications ranging from active pharmaceutical ingredient manufacturing to laboratory reagents and scientific research.

Recent filings

Filing Released Lang Actions
Dividend
Interim / Quarterly Report Classification · 84% confidence The document is a formal disclosure under SEBI LODR Regulations 30 and 33, announcing the audited standalone financial results for the quarter and financial year ended March 31, 2026, including full income statement, balance sheet, cash flow statements, notes, audit report, and dividend recommendation. It contains substantive financial data and tables, not merely a summary or external link, and is not a full annual report booklet. It represents a periodical financial report for a quarter/full-year end, fitting the “Interim / Quarterly Report” category. FY 2026
2026-05-21 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 88% confidence The document is an outcome of a Board meeting under SEBI LODR Regulation 33 that attaches the full audited standalone financial results for the quarter and year ended March 31, 2026, including income statement, balance sheet, cash flow statements, audit report, and notes. It contains substantive financial statements beyond mere highlights or a link, and is not a full annual report or management discussion. This aligns with the definition for an Interim/Quarterly Report (IR). FY 2026
2026-05-21 English
Board Meeting held today to consider and approve Audited Standalone Financial Results for the Quarter and Year ended on March 31, 2026
Interim / Quarterly Report Classification · 87% confidence The document is a detailed submission to the NSE and BSE of standalone audited financial results for the quarter and year ended March 31, 2026, including income statement, balance sheet, cash flow statement, notes, and an independent auditor’s report, filed under SEBI Listing Regulation 33. It is not a brief earnings highlight, nor a full annual report (10-K), nor merely an announcement of publication. Instead, it is the actual quarterly/interim financial report with substantive financial statements. Therefore it best fits the “Interim / Quarterly Report” (IR) category. FY 2026
2026-05-21 English
Outcome of Board Meeting held today to consider and approve Audited Standalone Financial Results and Dividend
Interim / Quarterly Report Classification · 87% confidence The document is the formal Outcome of the Board Meeting under SEBI LODR where the company discloses its Audited Standalone Financial Results for the quarter and financial year ended March 31, 2026. It includes full P&L, Balance Sheet, Cash Flow statements, notes, auditor’s report and declaration — i.e., substantive financial statements rather than mere headlines. This aligns with our definition of a periodic, comprehensive interim/quarterly report (IR), since it contains actual financial statements for the period. It is not merely an earnings teaser (ER) nor a full narrative annual report (10-K). FY 2026
2026-05-21 English
Kronox Lab Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Audited Standalone Financial ....
Regulatory Filings Classification · 75% confidence The document is a formal intimation to the stock exchanges under SEBI Listing Regulations announcing the date of a Board meeting to consider and approve audited financial results and recommend dividends. It does not contain the financial results themselves nor any changes in management. It is a regulatory announcement, not the report itself, so it falls into the general Regulatory Filings category.
2026-05-18 English
Kronox Lab Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 ,inter alia, to consider and approve Audited Financial Results ....
Regulatory Filings Classification · 95% confidence The document is a notice under SEBI Listing Regulations intimation of a Board of Directors meeting to consider audited financial results and dividends. It does not itself provide any financial results, changes in management, or detailed presentation materials. It is a general regulatory announcement of a board meeting. No other specific category (e.g., M&A, earnings release) applies. Under our taxonomy, this is best classified as a general regulatory filing (RNS).
2026-05-15 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.